Itci stock fda approval eigcaau

Itci stock fda approval

08.01.2021

Shanberg49335

ITCI Stock Price and Chart — NASDAQ:ITCI — TradingView ITCI was in our watch list for a while, and now it seems ready to go. Good insider buying from10% owner. We think it has Right now it is testing MA 200 resistance & it if can break above it can go much higher. On the option side we would consider August $12.50 calls @ $1.50 Intra-Cellular Therapies +86% premarket after Caplyta ... Dec 23, 2019 · Intra-Cellular Therapies (NASDAQ:ITCI) skyrockets 86% in premarket trading after the FDA approves its Caplyta (lumateperone) for the treatment of schizophrenia in adults.ITCI … HUGE WIN trading as ITCI stock RIPS on FDA approval ...

NEW YORK , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $29.50 per share.

Dec 23, 2019 · NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA ® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings ...

ITCI was in our watch list for a while, and now it seems ready to go. Good insider buying from10% owner. We think it has Right now it is testing MA 200 resistance & it if can break above it can go much higher. On the option side we would consider August $12.50 calls @ $1.50

12 Sep 2019 Intra-cellular therapies insider Christopher Alafi PhD bought $4.7 million of ITCI stock when investors sold the stock after FDA news. ITCI Intra-Cellular Therapies, Inc. daily Stock Chart 06:59AM, FDA Approves Intra-Cellular Therapies Novel Antipsychotic, CAPLYTA® (lumateperone) for the

Drugs@FDA: FDA-Approved Drugs

Investors flock to neuro drug makers after FDA approves ... Shares of Intra-Cellular jumped 203% in trading on Monday after the regulator approved Caplyta as a treatment for schizophrenia. The approval of Intra-Cellular Therapies Inc.'s (ITCI) schizophrenia drug Caplyta on Monday is the latest indicator that some drug developers are finally prioritizing psychiatric treatments despite the challenges of bringing them to market. FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic ... Dec 23, 2019 · NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA ® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings ... Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call. ITCI News Today (Intra-Cellular Therapies) | MarketBeat

What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?

Dec 23, 2019 · Intra-Cellular Therapies Inc. shares ITCI, -5.92% soared 83% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved a treatment for schizophrenia in 3 Biotechs Facing FDA Approvals by Year's End | The Motley ... Intra-Cellular Therapies (NASDAQ:ITCI) expects to hear from the FDA about the fate of its schizophrenia drug lumateperone by Dec. 27. The drug's novel mechanism acts on three different